[HTML][HTML] Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical …
…, M Aguilar-Guisado, F Al-Beidh… - BMC infectious …, 2021 - Springer
Background Convalescent plasma has been widely used to treat COVID-19 and is under
investigation in numerous randomized clinical trials, but results are publicly available only for a …
investigation in numerous randomized clinical trials, but results are publicly available only for a …
Interleukin-6 receptor antagonists in critically ill patients with Covid-19–preliminary report
…, AC Gordon, PR Mouncey, F Al-Beidh… - Medrxiv, 2021 - medrxiv.org
Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial
Importance Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19)
is limited. Objective To determine whether hydrocortisone improves outcome for …
is limited. Objective To determine whether hydrocortisone improves outcome for …
Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis
…, A Sönnerborg, JI Henter, AC Horne, F Al-Beidh… - Jama, 2021 - jamanetwork.com
Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …
[HTML][HTML] Levosimendan for the prevention of acute organ dysfunction in sepsis
…, AJ Mason, M Cross, F Al-Beidh… - … England Journal of …, 2016 - Mass Medical Soc
Background Levosimendan is a calcium-sensitizing drug with inotropic and other properties
that may improve outcomes in patients with sepsis. Methods We conducted a double-blind, …
that may improve outcomes in patients with sepsis. Methods We conducted a double-blind, …
The REMAP-CAP (randomized embedded multifactorial adaptive platform for community-acquired pneumonia) study. Rationale and design
There is broad interest in improved methods to generate robust evidence regarding best
practice, especially in settings where patient conditions are heterogenous and require multiple …
practice, especially in settings where patient conditions are heterogenous and require multiple …
[HTML][HTML] Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
Purpose To study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill
patients with coronavirus disease 2019 (COVID-19). Methods Critically ill adults with COVID-19 …
patients with coronavirus disease 2019 (COVID-19). Methods Critically ill adults with COVID-19 …
Transcriptomic signatures in sepsis and a differential response to steroids. From the VANISH randomized trial
DB Antcliffe, KL Burnham, F Al-Beidh… - American journal of …, 2019 - atsjournals.org
Rationale: There remains uncertainty about the role of corticosteroids in sepsis with clear
beneficial effects on shock duration, but conflicting survival effects. Two transcriptomic sepsis …
beneficial effects on shock duration, but conflicting survival effects. Two transcriptomic sepsis …
[HTML][HTML] PDGFRα demarcates the cardiogenic clonogenic Sca1+ stem/progenitor cell in adult murine myocardium
…, J Habib, I Macaulay, AJ De Smith, F Al-Beidh… - Nature …, 2015 - nature.com
Cardiac progenitor/stem cells in adult hearts represent an attractive therapeutic target for
heart regeneration, though (inter)-relationships among reported cells remain obscure. Using …
heart regeneration, though (inter)-relationships among reported cells remain obscure. Using …
Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 the REMAP-CAP COVID-19 immune modulation therapy domain …
BACKGROUND The interleukin-6 receptor antagonist tocilizumab improves outcomes in
critically ill patients with coronavirus disease 2019 (COVID-19). However, the effectiveness of …
critically ill patients with coronavirus disease 2019 (COVID-19). However, the effectiveness of …